Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-25-010051
Filing Date
2025-03-12
Accepted
2025-03-12 16:20:48
Documents
105
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2506300
2 ex19.htm EX-19 140639
3 ex23-1.htm EX-23.1 5326
4 ex31-1.htm EX-31.1 16472
5 ex31-2.htm EX-31.2 16288
6 ex32-1.htm EX-32.1 7029
7 ex32-2.htm EX-32.2 7412
8 form10-k_001.jpg GRAPHIC 28744
9 form10-k_002.jpg GRAPHIC 18398
  Complete submission text file 0001493152-25-010051.txt   11916301

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE erna-20241231.xsd EX-101.SCH 78349
11 XBRL CALCULATION FILE erna-20241231_cal.xml EX-101.CAL 109893
12 XBRL DEFINITION FILE erna-20241231_def.xml EX-101.DEF 366305
13 XBRL LABEL FILE erna-20241231_lab.xml EX-101.LAB 700364
14 XBRL PRESENTATION FILE erna-20241231_pre.xml EX-101.PRE 571453
108 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1808795
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-11460 | Film No.: 25732023
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)